GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » 1-Year ROIIC %

Relief Therapeutics Holding (Relief Therapeutics Holding) 1-Year ROIIC % : -15.81% (As of Jun. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Relief Therapeutics Holding's 1-Year ROIIC % for the quarter that ended in Jun. 2023 was -15.81%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Relief Therapeutics Holding's 1-Year ROIIC % or its related term are showing as below:

RLFTF's 1-Year ROIIC % is ranked worse than
55.4% of 1462 companies
in the Biotechnology industry
Industry Median: -2.96 vs RLFTF: -15.81

Relief Therapeutics Holding 1-Year ROIIC % Historical Data

The historical data trend for Relief Therapeutics Holding's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding 1-Year ROIIC % Chart

Relief Therapeutics Holding Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.74 0.73 -128.60 -8.34 -0.13

Relief Therapeutics Holding Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.30 -8.34 -15.97 -0.13 -15.81

Competitive Comparison of Relief Therapeutics Holding's 1-Year ROIIC %

For the Biotechnology subindustry, Relief Therapeutics Holding's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's 1-Year ROIIC % falls into.



Relief Therapeutics Holding 1-Year ROIIC % Calculation

Relief Therapeutics Holding's 1-Year ROIIC % for the quarter that ended in Jun. 2023 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -27.7095 (Jun. 2023) - -40.8968 (Jun. 2022) )/( 124.859 (Jun. 2023) - 201.746 (Jun. 2022) )
=13.1873/-76.887
=-17.15%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Relief Therapeutics Holding  (OTCPK:RLFTF) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Relief Therapeutics Holding 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (Relief Therapeutics Holding) Headlines

From GuruFocus

Relief Therapeutics to Participate in January Investor Meetings

By ACCESSWIRE ACCESSWIRE 12-14-2022

Relief Therapeutics Announces Executive Leadership Team Changes

By ACCESSWIRE ACCESSWIRE 12-08-2022